CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer

Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok · 2026

Read CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer by Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13551694.txt.

Description

Tony Yu, leading seven colleagues, published a 2026 study hunting for drug combinations that make small cell lung cancer respond to PARP inhibitors, a class that blocks DNA repair. Responses vary, so the team ran a genome-wide CRISPR screen in two cancer cell lines under the PARP inhibitor olaparib, watching which gene losses made cells die. Follow-up tests used gene knockdown and cell viability assays.

Losing regulators that restrain the mTOR pathway sensitized cells, pointing toward autophagy, the cell's recycling system, as a partner target. Combining a newer PARP inhibitor, AZD5305, with an autophagy inhibitor, GNS561, acted synergistically in cell lines and worked in mouse tumors grown from those lines. The authors propose the pairing for further development.

Catalog record

CREATORTony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44705
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13551694

Browse the full library · About the Tower of Babel